Catalyst Event
Abbott Laboratories (ABT) · Earnings Release
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/16/2026, 12:00:00 AM
Abbott's first-quarter 2026 financial results announcement and conference call on April 16, 2026, for which market analysts estimate a >=5% price impact, are scheduled.
Korean Translation
시장 분석가들이 5% 이상의 주가 영향을 예상하는 Abbott의 2026년 1분기 실적 발표 및 컨퍼런스 콜이 2026년 4월 16일로 예정됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
First quarter 2026 earnings release and conference call, which is estimated to have a >=10% price impact, is scheduled.
4/30/2026, 12:00:00 AM
Johnson & Johnson (JNJ) · Earnings Release
Johnson & Johnson's Q1 2026 earnings release is scheduled for April 14, 2026, before the market opens scheduled.
4/14/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
U.S. Food and Drug Administration (FDA) decision on orforglipron, an oral weight-loss pill, is expected. The target action date was previously extended, and a >=10% price impact is expected.
4/10/2026, 12:00:00 AM
Oracle Corp (ORCL) · Other
Veritone announced on March 26, 2026, a multi-year agreement to migrate its AI solutions to Oracle Cloud Infrastructure (OCI), signaling a strategic customer win for Oracle's cloud business.
3/26/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
S&P Global Ratings is expected to downgrade Abbott's credit rating to 'A+' from 'AA-' on March 24, 2026, following the Exact Sciences acquisition; market analysts estimate a >=10% price impact.
3/24/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
On March 24, 2026, Medtronic lowered its fiscal year 2026 non-GAAP EPS guidance to a range of $5.50-$5.54, down from the previous $5.62-$5.66. The revision was due to dilution from the MiniMed IPO and a one-time charge related to the early FDA approval of the MiniMed Flex insulin pump. (Estimated 1-5% impact due to guidance revision).
3/24/2026, 12:00:00 AM